Patient-activated transvenous cardiac stimulation for the treatment of supraventricular and ventricular tachycardia

Geoffrey O. Hartzler, David Holmes, Michael J. Osborn

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Recurrent, drug-refractory sustained tachycardias present a difficult management problem. After invasive electrophysiologic study and extensive antiarrhythmic drug testing, a permanent transvenous lead system and radiofrequency stimulator that required patient activation for burst pacing were implanted in eight patients with refractory Supraventricular tachycardia and in nine patients with refractory ventricular tachycardia. In a follow-up period of 2 to 28.5 months (mean 12) each patient has successfully terminated multiple episodes of recurrent tachycardia without complicatlon. This therapeutic approach has allowed a reduction in antiarrhythmic drug dosage and adverse effects, has obviated the need for frequent hospital admissions resulting from recurrent tachycardia, and has met with excellent patient acceptance.

Original languageEnglish (US)
Pages (from-to)903-909
Number of pages7
JournalThe American journal of cardiology
Volume47
Issue number4
DOIs
StatePublished - Jan 1 1981

Fingerprint

Supraventricular Tachycardia
Ventricular Tachycardia
Tachycardia
Anti-Arrhythmia Agents
Patient Participation
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Patient-activated transvenous cardiac stimulation for the treatment of supraventricular and ventricular tachycardia. / Hartzler, Geoffrey O.; Holmes, David; Osborn, Michael J.

In: The American journal of cardiology, Vol. 47, No. 4, 01.01.1981, p. 903-909.

Research output: Contribution to journalArticle

@article{8e6282c241714137a2ddfb2a5cf1b458,
title = "Patient-activated transvenous cardiac stimulation for the treatment of supraventricular and ventricular tachycardia",
abstract = "Recurrent, drug-refractory sustained tachycardias present a difficult management problem. After invasive electrophysiologic study and extensive antiarrhythmic drug testing, a permanent transvenous lead system and radiofrequency stimulator that required patient activation for burst pacing were implanted in eight patients with refractory Supraventricular tachycardia and in nine patients with refractory ventricular tachycardia. In a follow-up period of 2 to 28.5 months (mean 12) each patient has successfully terminated multiple episodes of recurrent tachycardia without complicatlon. This therapeutic approach has allowed a reduction in antiarrhythmic drug dosage and adverse effects, has obviated the need for frequent hospital admissions resulting from recurrent tachycardia, and has met with excellent patient acceptance.",
author = "Hartzler, {Geoffrey O.} and David Holmes and Osborn, {Michael J.}",
year = "1981",
month = "1",
day = "1",
doi = "10.1016/0002-9149(81)90192-2",
language = "English (US)",
volume = "47",
pages = "903--909",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Patient-activated transvenous cardiac stimulation for the treatment of supraventricular and ventricular tachycardia

AU - Hartzler, Geoffrey O.

AU - Holmes, David

AU - Osborn, Michael J.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Recurrent, drug-refractory sustained tachycardias present a difficult management problem. After invasive electrophysiologic study and extensive antiarrhythmic drug testing, a permanent transvenous lead system and radiofrequency stimulator that required patient activation for burst pacing were implanted in eight patients with refractory Supraventricular tachycardia and in nine patients with refractory ventricular tachycardia. In a follow-up period of 2 to 28.5 months (mean 12) each patient has successfully terminated multiple episodes of recurrent tachycardia without complicatlon. This therapeutic approach has allowed a reduction in antiarrhythmic drug dosage and adverse effects, has obviated the need for frequent hospital admissions resulting from recurrent tachycardia, and has met with excellent patient acceptance.

AB - Recurrent, drug-refractory sustained tachycardias present a difficult management problem. After invasive electrophysiologic study and extensive antiarrhythmic drug testing, a permanent transvenous lead system and radiofrequency stimulator that required patient activation for burst pacing were implanted in eight patients with refractory Supraventricular tachycardia and in nine patients with refractory ventricular tachycardia. In a follow-up period of 2 to 28.5 months (mean 12) each patient has successfully terminated multiple episodes of recurrent tachycardia without complicatlon. This therapeutic approach has allowed a reduction in antiarrhythmic drug dosage and adverse effects, has obviated the need for frequent hospital admissions resulting from recurrent tachycardia, and has met with excellent patient acceptance.

UR - http://www.scopus.com/inward/record.url?scp=0019508312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019508312&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(81)90192-2

DO - 10.1016/0002-9149(81)90192-2

M3 - Article

C2 - 7211706

AN - SCOPUS:0019508312

VL - 47

SP - 903

EP - 909

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -